BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kessler J, Hohmann T, Güttler A, Petrenko M, Ostheimer C, Hohmann U, Bache M, Dehghani F, Vordermark D. Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers (Basel) 2019;11:E889. [PMID: 31242696 DOI: 10.3390/cancers11060889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu K, Ji Y, Liu M, Shen F, Xiong X, Gu L, Lu T, Ye Y, Feng S, He J. High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma. Front Immunol 2022;13:881453. [DOI: 10.3389/fimmu.2022.881453] [Reference Citation Analysis]
2 Wei S, Li J. Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma. J Healthc Eng 2022;2022:3477918. [PMID: 35211253 DOI: 10.1155/2022/3477918] [Reference Citation Analysis]
3 Wang ZH, Xiao XL, Zhang ZT, He K, Hu F. A Radiomics Model for Predicting Early Recurrence in Grade II Gliomas Based on Preoperative Multiparametric Magnetic Resonance Imaging. Front Oncol 2021;11:684996. [PMID: 34540662 DOI: 10.3389/fonc.2021.684996] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Li C, Yi C, Chen Y, Xi S, Guo C, Yang Q, Wang J, Sai K, Zhang J, Ke C, Chen F, Lv Y, Zhang X, Chen Z. Identify glioma recurrence and treatment effects with triple-tracer PET/CT. BMC Med Imaging 2021;21:92. [PMID: 34059015 DOI: 10.1186/s12880-021-00624-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Vallée A, Lecarpentier Y, Vallée JN. Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification. Biomedicines 2021;9:619. [PMID: 34070746 DOI: 10.3390/biomedicines9060619] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Di Gregorio E, Miolo G, Saorin A, Steffan A, Corona G. From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. Int J Mol Sci 2021;22:5574. [PMID: 34070384 DOI: 10.3390/ijms22115574] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 van Noorden CJF, Hira VVV, van Dijck AJ, Novak M, Breznik B, Molenaar RJ. Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy? Cells 2021;10:705. [PMID: 33810170 DOI: 10.3390/cells10030705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Naz H, Bashir Q, Rashid N, Shahzad N. Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan. Ann Hum Genet 2021;85:73-9. [PMID: 33226123 DOI: 10.1111/ahg.12409] [Reference Citation Analysis]
9 Biedermann J, Preussler M, Conde M, Peitzsch M, Richter S, Wiedemuth R, Abou-El-Ardat K, Krüger A, Meinhardt M, Schackert G, Leenders WP, Herold-Mende C, Niclou SP, Bjerkvig R, Eisenhofer G, Temme A, Seifert M, Kunz-Schughart LA, Schröck E, Klink B. Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers (Basel) 2019;11:E2028. [PMID: 31888244 DOI: 10.3390/cancers11122028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Tabatabai G, Wakimoto H. Glioblastoma: State of the Art and Future Perspectives. Cancers (Basel) 2019;11:E1091. [PMID: 31370300 DOI: 10.3390/cancers11081091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]